Retropharyngeal Abscess Treatment Market Size in 2022, Increasing demand, Growth strategies, Forecast to 2028

A retropharyngeal abscess is a serious infection, usually starts in the lymph nodes, characterised by collection of pus at the back of the throat. Retropharyngeal abscess typically occurs in children under the age of eight, sometimes it can also affect adults. The symptoms of retropharyngeal abscess include difficulty or noisy breathing, difficulty and pain while swallowing, drooling, severe cough, severe throat pain, neck stiffness or swelling, muscle spasms in the neck among others. Retropharyngeal abscess is generally preceded by upper respiratory infections mostly a middle ear or sinus infection.Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Retropharyngeal Abscess Treatment estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of percent during the forecast period 2022-2028.The USA market for Retropharyngeal Abscess Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Retropharyngeal Abscess Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Retropharyngeal Abscess Treatment is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key companies of Retropharyngeal Abscess Treatment include Pfizer, Sanofi, Novartis, Johnson & Johnson, GlaxoSmithKline, Merck, AstraZeneca, Mylan and Teva pharmaceutical, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.